VivoSeq
Other

Paraganglioma

59

Pipeline Programs↗

8

Active Trials↗

31

Companies Involved↗

Paraganglioma is a moderately active landscape with 59 programs across 31 companies. The most active players are Genzyme, a Sanofi Company, Jazz Pharmaceuticals, Merck & Co.. 25 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

62/100

Pipeline Velocity

11/100

Mech. Concentration

5/100

Completion Rate

67/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Genzyme, a Sanofi Company

1 program

Phase 1Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

2 programs

Phase 2Merck & Co. logo

Merck & Co.

2 programs

Phase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

2 programs

Phase 2GSK logo

GSK

1 program

Phase 2B

Biotech Pharmaceutical Co., Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

50 of 60 classified programs — the dominant modality here.

17%ALL OTHERSMonoclonal antibody610%Protein / enzyme12%Peptide12%Vaccine12%Radiopharmaceutical12%

Small molecule leads; the ring shows all 60 classified programs, each share of the total. Modality classified for 100% of 61 pipeline programs.

Analysis

Trial Status

23

clinical trials

Completed8 · 35%
Recruiting6 · 26%
Active, not recruiting2 · 9%
Terminated2 · 9%
Withdrawn2 · 9%
Unknown status2 · 9%
Other1 · 4%

Clinical Trials

Trial Activity

23 trials

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
Recruiting·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 2·NCT07282587·90 enrolled
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT03206060·130 enrolled
In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
Recruiting·—·Phase 1·NCT05636540·30 enrolled
Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma
Recruiting·PPeking Union Medical College Hospital·N/A·NCT07288931·40 enrolled
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT06479811·120 enrolled
Impact of Environmental Exposures on Tumor Risk in Subjects at Risk of Hereditary SDHx-related Paragangliomas - National Study
Recruiting·AAssistance Publique - Hôpitaux de Paris·N/A·NCT06408402·1,300 enrolled
Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma
Active, not recruiting·—·Phase 2·NCT03839498·6 enrolled
LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)
Active, not recruiting·—·Phase 2·NCT03946527·10 enrolled
ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
Completed·MMolecular Insight Pharmaceuticals, Inc.·Phase 1·NCT00339131·24 enrolled
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Completed·National Cancer Institute (NCI)·Phase 2·NCT01967576·14 enrolled
The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma
Completed·PPeking Union Medical College Hospital·Phase 2·NCT04860700·27 enrolled
First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma
Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT01371201·78 enrolled
Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02302833·21 enrolled
Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
Completed·UUniversity Health Network, Toronto·Phase 2·NCT00843037·25 enrolled
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Completed·MMolecular Insight Pharmaceuticals, Inc.·Phase 1/2·NCT00458952·24 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)